![a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/354037225/figure/fig3/AS:1080245671211019@1634562046489/a-Overall-survival-from-LM-diagnosis-for-the-total-population-b-Kaplan-Meier-curve_Q320.jpg)
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
![Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western](https://www.thelancet.com/cms/asset/d0a6e5f4-955a-4c77-9dac-0c94de293490/gr1.jpg)
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western
![Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0346/asset/images/medium/figure2.gif)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
AstraZeneca's TAGRISSO® (osimertinib) shows potential as a new standard of care in 1st-line EGFR-mutated non-small cell lung cancer at ESMO 2017 Congress
![The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-08449-w/MediaObjects/41598_2022_8449_Fig1_HTML.png)
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
![a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/354037225/figure/fig5/AS:1080245671198846@1634562046729/a-Overall-survival-from-LM-diagnosis-for-the-total-population-b-Kaplan-Meier-curve_Q320.jpg)
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
![Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/3c519893-23a9-4078-946a-1fd1e40feff8/gr3.jpg)
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
![An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC) An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)](https://www.ilcn.org/wp-content/uploads/2021/12/ADAURA.jpg)
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
![Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2016/AURA3.png/jcr:content/renditions/cq5dam.web.320.AURA3.png)
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
![TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc) TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~31496~24~image8.png)
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
![Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00794-6/MediaObjects/11523_2021_794_Fig1_HTML.png)
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
![Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2016/AURA3.png/jcr:content/renditions/cq5dam.web.480.AURA3.png)
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
![TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc) TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~31496~24~image9.png)
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
![New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/graph.png/jcr:content/renditions/cq5dam.web.480.graph.png)
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
![New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/graph.png/jcr:content/renditions/cq5dam.web.320.graph.png)
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
![Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology](https://www.jto.org/cms/asset/acef0ded-e540-4a4e-8df1-364ab572d38e/gr1.jpg)